Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 87 clinical trials
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

This study is an open-label, international, multi-center, Phase 2 study in adult patients with recurrent, locally-advanced or metastatic solid tumors, which harbor the NRG1 gene fusion.

growth factor
metastatic malignant solid tumor
blood transfusion
ffpe
metastatic solid tumor
  • 0 views
  • 19 Feb, 2024
Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors

This is an open, two-stage, phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of AB011 injection in patients with CLDN18.2-positive advanced solid tumors.

treatment regimen
solid tumour
solid neoplasm
  • 0 views
  • 19 Feb, 2024
Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

Giving avelumab together with M6620 may help to control DDR deficient metastatic or unresectable solid tumors.

monoclonal antibodies
systemic therapy
RAD51D
estimated creatinine clearance
liver metastasis
  • 0 views
  • 19 Feb, 2024
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

This is a phase I, open-label, non-randomized study that will enroll pediatric and young adult research participants with relapsed or refractory non-CNS solid tumors to evaluate the safety, feasibility, and efficacy of administering T cell products derived from the research participant's blood that have been genetically modified to express a …

iobenguane
tumors in children
cetuximab
biotherapy
steroid therapy
  • 0 views
  • 19 Feb, 2024
Dose Escalation of DF6002 in Patients With Advanced Solid Tumors and Expansion in Selected Indications

This study is a Phase 1/2, open-label, dose-escalation study with a consecutive parallel-group efficacy expansion study, designed to determine the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of DF6002 as monotherapy and in combination with pembrolizumab.

advanced renal cell carcinoma
growth factor
carcinoma
renal pelvis
BRAF
  • 0 views
  • 19 Feb, 2024
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

systemic therapy
metastasis
measurable disease
oophorectomy
bilateral oophorectomy
  • 0 views
  • 19 Feb, 2024
A First-in-human Study Using BDC-1001 in Advanced and HER2-Expressing Solid Tumors

A first-in-human study using BDC-1001 in HER2 expressing advanced malignancies

metastasis
measurable disease
gene amplification
cancer
pembrolizumab
  • 0 views
  • 19 Feb, 2024
ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with BAY1895344 in combination with niraparib. In addition researchers want to find for patients the optimal dose of BAY1895344 in combination with niraparib, how the drug is tolerated and …

peritoneal cancer
line of therapy
niraparib
ATR
fallopian tube
  • 0 views
  • 19 Feb, 2024
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations.

radiopharmaceutical
bone marrow procedure
pleural effusion
growth factor
tipifarnib
  • 0 views
  • 19 Feb, 2024
A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric/Gastroesophageal Junction (GEJ) Cancer

The objective of this study is to assess the safety, efficacy, and pharmacokinetics of MRG002, as well as the immunogenicity as defined by the incidence of anti-drug antibody (ADA) of MRG002 in patients with HER2-positive advanced solid tumors and locally advanced or metastatic gastric/gastroesophageal junction (GEJ) cancer.

  • 0 views
  • 19 Feb, 2024